All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PDL1 (CPS < 1) PDL1 (CPS >1) smoker (current or former) smoker (Current) smoker (Former) smoker (never) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Extensive stage SCLC (Es-SCLC), immune chekpoint inhibitors vs. placebo, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 451 (N ; all population), 2019 0.84 [0.69; 1.02]
CheckMate 451 (NI ; all population), 2019 0.92 [0.75; 1.12]
0.88 [0.76 ; 1.01 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 0% 1,109 moderate not evaluable progression or deaths (PFS)detailed results CheckMate 451 (N ; all population), 2019 0.67 [0.56; 0.81]
CheckMate 451 (NI ; all population), 2019 0.72 [0.60; 0.87]
0.69 [0.61 ; 0.79 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 0% 1,109 moderate not evaluable objective responses (ORR)detailed results CheckMate 451 (N ; all population), 2019 2.93 [1.44; 5.95]
CheckMate 451 (NI ; all population), 2019 2.33 [1.11; 4.90]
2.63 [1.57 ; 4.39 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 0% 1,109 moderate not evaluable TRAE (any grade)detailed results CheckMate 451 (N ; all population), 2019 1.49 [1.06; 2.08]
CheckMate 451 (NI ; all population), 2019 4.23 [2.89; 6.20]
2.50 [0.90 ; 6.96 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 94% 1,109 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 451 (N ; all population), 2019 1.59 [0.90; 2.79]
CheckMate 451 (NI ; all population), 2019 12.44 [7.59; 20.41]
4.47 [0.59 ; 33.57 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 97% 1,109 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 451 (N ; all population), 2019 0.98 [0.06; 15.78]
CheckMate 451 (NI ; all population), 2019 7.05 [0.86; 57.70]
3.27 [0.50 ; 21.53 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 19% 1,109 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results Out of scale CheckMate 451 (N ; all population), 2019 20.14 [4.80; 84.52]
CheckMate 451 (NI ; all population), 2019 60.82 [14.79; 250.13]
35.24 [11.93 ; 104.09 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 14% 1,109 moderate not evaluable 0.5 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-08-16 08:44 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 281,194,162,172
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743
